Neuroblastoma: Issues in Transplantation

Grupp, Stephan A.; Asgharzadeh, Shahab; Yanik, Gregory A.

doi:10.1016/j.bbmt.2011.10.020

Cited by 18 publications

(14 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the most effective conditioning regimen has not been definitively demonstrated. In the earliest trials, total body irradiation was used , but more recent trials have avoided radiation due to concerns regarding late effects and the development of secondary malignancies . In the United States, CEM has been the backbone of COG trials and is the most common regimen used for patients on or off research protocols.…”

Section: Discussionmentioning

confidence: 99%

Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers

Elborai

Hafez

Moussa

et al. 2015

Pediatric Transplantation

View full text Add to dashboard Cite

The outcome for advanced neuroblastoma has improved with combined modality therapy: induction chemotherapy, surgery, and consolidation with high-dose chemotherapy/autologous HSCT, followed by local radiation, cisretinoic acid, and recently antibody therapy. In the United States, the most common conditioning regimen is CEM, while in Europe/Middle East, Bu/Mel has been widely used; it remains unclear which regimen has the best outcome. Assess renal, hepatic, and infectious toxicity through Day+100 in 2 different regimens. Retrospective comparison between CEM-DFCHCC Boston and Bu/Mel- CCHE-57357. Thirty-five patients, median age 4, in Boston (2007-2011) and 38 patients, median age 3, in Cairo (2009-2011). Renal toxicity; creatinine was significantly higher in CEM than Bu/Mel: 57% (median day+90) vs. 29% (median>day+100), p = 0.004. One CEM patient died from renal dialysis at day+19. Hepatic toxicity was significantly higher in CEM than Bu/Mel: 80% (median day+26) vs. 58% (median day+60), p = 0.04. In infectious complications with CEM 14%, bacteremia (n = 4) and fungemia (n = 1), 3 had culture-negative sepsis requiring vasopressors. With Bu/Mel 18%, bacteremia (n = 7), none required pressors, p = 0.4. Bu/Mel was associated with less acute hepatic and renal toxicity and thus may be preferable for preserving organ functions.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers

Elborai

Hafez

Moussa

et al. 2015

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

“…Given that most patients with high-risk neuroblastoma will receive autologous hematopoietic stem cell transplantation (HSCT; ref. 38), a small aliquot from an autologous stem cell collection may be used conveniently as an alternative starting cells for CD56 þ activation. Our previous study in patients with acute myelogenous leukemia (AML) infused a median of 3 Â 10 7 CD56 þ cells/kg (31).…”

Section: Discussionmentioning

confidence: 99%

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Looking ahead, we propose a comprehensive translational research roadmap that takes advantage of high throughput drug screening, new generations of animal models, and study designs to mimic real clinical settings. We will not discuss modern evolutions of chemotherapy including those in the myeloablative [G] setting, which have been summarized extensively by other investigators 9 .…”

mentioning

confidence: 99%

Neuroblastoma: developmental biology, cancer genomics and immunotherapy

2013

View full text Add to dashboard Cite

Neuroblastoma is a solid tumor that arises from the developing sympathetic nervous system. Over the past decade, our understanding of this disease has advanced tremendously. The future challenge is to apply the knowledge gained toward developing risk-based therapies and ultimately improving outcome. Here we review the key discoveries in the developmental biology, molecular genetics, and immunology of neuroblastoma, as well as new translational tools to bring these promising scientific advances into the clinic.

show abstract

Neuroblastoma: Issues in Transplantation

Cited by 18 publications

References 67 publications

Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers

Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers

Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma

Neuroblastoma: developmental biology, cancer genomics and immunotherapy

Contact Info

Product

Resources

About